why choose us

First received: January 17, 2023

Clinical Trial: Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Renal Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesotheliom

Brief Summary: To find a recommended dose of donated NK cells that can be given with lymphodepleting chemotherapy to patients with advanced renal cell carcinoma, mesothelioma, or osteosarcoma.The effects of this therapy will also be studied.

Read more